6.7 0.44 (7.03%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 7.82 | 1-year : | 9.14 |
Resists | First : | 6.69 | Second : | 7.82 |
Pivot price | 6.16 | |||
Supports | First : | 6.26 | Second : | 6 |
MAs | MA(5) : | 6.2 | MA(20) : | 6.22 |
MA(100) : | 6.57 | MA(250) : | 7.86 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 52 | D(3) : | 25.7 |
RSI | RSI(14): 61.7 | |||
52-week | High : | 15.42 | Low : | 4.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PRPO ] has closed It is unclear right now based on current values. 43.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 6.71 - 6.74 | 6.74 - 6.76 |
Low: | 5.95 - 5.98 | 5.98 - 6 |
Close: | 6.65 - 6.7 | 6.7 - 6.75 |
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Sat, 23 Mar 2024
Precipio (NASDAQ:PRPO) Shares Pass Below 200-Day Moving Average of $6.58 - Defense World
Fri, 15 Mar 2024
Precipio (NASDAQ:PRPO) Share Price Crosses Below 200-Day Moving Average of $6.61 - Defense World
Thu, 16 Nov 2023
When Will Precipio, Inc. (NASDAQ:PRPO) Breakeven? - Yahoo Finance
Fri, 22 Sep 2023
Precipio (NASDAQ: PRPO) to jump 2,000% at the open - nominal price change, technical - Dhaka Tribune
Thu, 21 Sep 2023
Precipio announces 1-for-20 reverse stock split to regain Nasdaq compliance (NASDAQ:PRPO) - Seeking Alpha
Sun, 13 Aug 2023
Precipio, Inc.'s (NASDAQ:PRPO) Shares Not Telling The Full Story - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Diagnostics & Research
|
|
Shares Out | 1 (M) |
Shares Float | 1 (M) |
Held by Insiders | 3.6 (%) |
Held by Institutions | 10.4 (%) |
Shares Short | 10 (K) |
Shares Short P.Month | 9 (K) |
EPS | -7.47 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 9.36 |
Profit Margin | -68.4 % |
Operating Margin | -32.1 % |
Return on Assets (ttm) | -26.7 % |
Return on Equity (ttm) | -58 % |
Qtrly Rev. Growth | 104 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 9.33 |
EBITDA (p.s.) | -5.48 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -5 (M) |
Levered Free Cash Flow | -2 (M) |
PE Ratio | -0.9 |
PEG Ratio | -0.1 |
Price to Book value | 0.71 |
Price to Sales | 0.71 |
Price to Cash Flow | -1.85 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |